Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

Journal of Clinical Investigation

Volumn 116, Issue 9, 2006, Pages 2543-2551

  McMahan, Rachel H ^a   McWilliams, Jennifer A ^a   Jordan, Kimberly R ^a   Dow, Steven W ^b   Wilson, Darcy B ^c   Slansky, Jill E ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE LIBRARY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIBODY AFFINITY; ARTICLE; CELL ACTIVITY; CELL CLONING; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; COMBINATORIAL LIBRARY; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CANCER VACCINES; DNA PRIMERS; DRUG DESIGN; HUMANS; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; PEPTIDE LIBRARY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33748319512     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI26936     Document Type: Article

References (64)

1. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
2. Marincola, F.M., Jaffee, E.M., Hicklin, D.J., and Ferrone, S. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181-273.
3. Gorelik, L., and Flavell, R.A. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7:1118-1122.
4. Niethammer, A.G., et al. 2002. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8:1369-1375.
5. Novellino, L., Castelli, C., and Parmiani, G. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54:187-207.
6. Dyall, R., et al. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553-1561.
7. Overwijk, W.W., et al. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
8. Valmori, D., et al. 1999. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11:1971-1980.
9. Tangri, S., et al. 2001. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194:833-846.
10. Parkhurst, M.R., et al. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201- binding residues. J. Immunol. 157:2539-2548.
11. Hernandez, J., et al. 2004. Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur. J. Immunol. 34:2331-2341.
12. Slansky, J.E., et al. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 13:529-538.
13. de Visser, K.E., et al. 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167:3818-3828.
14. Hoffmann, T.K., et al. 2002. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J. Immunol. 168:1338-1347.
15. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
16. Anichini, A., et al. 1999. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 190:651-667.
17. Fong, L., et al. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 98:8809-8814.
18. Skipper, J.C., et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183:527-534.
19. Rubio, V., et al. 2003. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9:1377-1382.
20. Molldrem, J.J., et al. 2003. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111:639-647. doi:10.1172/JCI200316398.
21. Stuge, T.B., et al. 2004. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1:e28.
22. Lee, P.P., et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
23. Valitutti, S., Muller, S., Dessing, M., and Lanzavecchia, A. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1917-1921.
24. Alexander-Miller, M.A., Leggatt, G.R., Sarin, A., and Berzofsky, J.A. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485-492.
25. Kalergis, A.M., et al. 2001. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2:229-234.
26. Holler, P.D., and Kranz, D.M. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity. 18:255-264.
27. Rosette, C., et al. 2001. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity. 15:59-70.
28. Kersh, G.J., and Allen, P.M. 1996. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 184:1259-1268.
29. Matsui, K., Boniface, J.J., Steffner, P., Reay, P.A., and Davis, M.M. 1994. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci. U. S. A. 91:12862-12866.
30. Yu, X.Z., Martin, P.J., and Anasetti, C. 2003. CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. J. Immunol. 170:3002-3006.
31. Ueno, T., Tomiyama, H., Fujiwara, M., Oka, S., and Takiguchi, M. 2004. Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions. J. Immunol. 173:5451-5457.
32. Sykulev, Y., Vugmeyster, Y., Brunmark, A., Ploegh, H.L., and Eisen, H.N. 1998. Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity. 9:475-483.
33. O'Connor, D.H., et al. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493-499.
34. Corbett, T.H., Griswold, D.P., Jr., Roberts, B.J., Peckham, J.C., and Schabel, F.M., Jr. 1977. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer. 40:2660-2680.
35. Huang, A.Y., et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. U. S. A. 93:9730-9735.
36. Luznik, L., et al. 2003. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood. 101:1645-1652.
37. Rodolfo, M., et al. 1994. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int. J. Cancer. 57:440-447.
38. Nino-Vasquez, J.J., et al. 2004. A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol. Immunol. 40:1063-1074.
39. O'Herrin, S.M., et al. 1997. Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors. J. Exp. Med. 186:1333-1345.
40. Sharma, A.K., et al. 2001. Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts. J. Biol. Chem. 276:21443-21449.
41. Kersh, G.J., et al. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. J. Immunol. 166:3345-3354.
42. al-Ramadi, B.K., Jelonek, M.T., Boyd, L.F., Margulies, D.H., and Bothwell, A.L. 1995. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J. Immunol. 155:662-673.
43. Fahmy, T.M., Bieler, J.G., Edidin, M., and Schneck, J.P. 2001. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity. 14:135-143.
44. Balendiran, G.K., et al. 1997. The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. Proc. Natl. Acad. Sci. U. S. A. 94:6880-6885.
45. Speir, J.A., et al. 1998. Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes. Immunity. 8:553-562.
46. Khilko, S.N., et al. 1993. Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity. J. Biol. Chem. 268:15425-15434.
47. Dutoit, V., Guillaume, P., Cerottini, J.C., Romero, P., and Valmori, D. 2002. Dissecting TCR-MHC/ peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur. J. Immunol. 32:3285-3293.
48. Dow, S.W., et al. 1999. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163:1552-1561.
49. Zippelius, A., et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865-2873.
50. Betts, M.R., et al. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods. 281:65-78.
51. Dighe, A.S., Richards, E., Old, L.J., and Schreiber, R.D. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1:447-456.
52. Robinson, R.A., and Lee, D.R. 1996. Studies of tumpeptide analogs define an alternative anchor that can be utilized by Ld ligands lacking the consensus P2 anchor. J. Immunol. 156:4266-4273.
53. Ikeda, H., Old, L.J., and Schreiber, R.D. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13:95-109.
54. Anderton, S.M., Radu, C.G., Lowrey, P.A., Ward, E.S., and Wraith, D.C. 2001. Negative selection during the peripheral immune response to antigen. J. Exp. Med. 193:1-11.
55. Vezys, V., and Lefrancois, L. 2002. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J. Immunol. 169:6677-6680.
56. Hernandez, J., Aung, S., Redmond, W.L., and Sherman, L.A. 2001. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194:707-717.
57. Huang, C.T., et al. 2003. CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J. Immunol. 170:3945-3953.
58. Zajac, A.J., et al. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.
59. Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R., and Ahmed, R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
60. Crawford, F., Kozono, H., White, J., Marrack, P., and Kappler, J. 1998. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity. 8:675-682.
61. Kappler, J., White, J., Kozono, H., Clements, J., and Marrack, P. 1994. Binding of a soluble alpha beta T-cell receptor to superantigen/major histocompatibility complex ligands. Proc. Natl. Acad. Sci. U. S. A. 91:8462-8466.
62. Templeton, N.S., et al. 1997. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15:647-652.
63. Zaks, K., et al. 2006. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176:7335-7345.
64. Overwijk, W.W., Surman, D.R., Tsung, K., and Restifo, N.P. 1997. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 12:117-123.